OxfordBiomedica |

AAV platform

We work across key viral vector delivery systems including adeno-associated virus (AAV) to provide innovative solutions to cell and gene therapy biotechnology and biopharma companies.

LentiVector^® platform

We have built a sector leading lentiviral delivery system, LentiVector^® platform which is already used in commercially available treatments.

Overview

Discover Oxford Biomedica - a leading gene and cell therapy with over 25 years of experience.

Get in touch

Contact form

Press releases

Interim results for the six months ended 30 June 2022

15 September 2022

Oxford Biomedica Solutions signs agreement with new partner for AAV platform

14 September 2022

Oxford Biomedica signs Licence & Supply Agreement with new partner for LentiVector® platform for late-stage clinical programme

07 September 2022

Oxford Biomedica notes Homology Medicines’ quarterly report and confirms financials for Oxford Biomedica Solutions LLC are in line with expectations

16 August 2022

Platform

Our viral vector platform is enabling our customers to bring next generation treatments for serious diseases to market.

Services

OXB is an innovative leading viral vector specialist – Lenti, AAV, Adeno and beyond - focused on delivering life changing therapies to patients.

InvestorsGo

PipelineGo